 INmune Bio, Inc. INMB the Company, a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president Europe of the International Society of Cell Gene Therapy ISCT and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer. 